Which has better valuation and earnings, RGEN or BIO?

Bio-Rad Laboratories has higher revenue and earnings than Repligen. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Repligen $738.26M 12.60 $48.89M $0.73 225.71 Bio-Rad Laboratories $2.58B 3.69 $759.90M $8.25 43.14

Does the media prefer RGEN or BIO?

In the previous week, Bio-Rad Laboratories had 11 more articles in the media than Repligen. MarketBeat recorded 18 mentions for Bio-Rad Laboratories and 7 mentions for Repligen. Repligen's average media sentiment score of 1.20 beat Bio-Rad Laboratories' score of 0.72 indicating that Repligen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Rad Laboratories 6 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TECH or BIO?

In the previous week, Bio-Rad Laboratories had 11 more articles in the media than Bio-Techne. MarketBeat recorded 18 mentions for Bio-Rad Laboratories and 7 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.36 beat Bio-Rad Laboratories' score of 0.72 indicating that Bio-Techne is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Rad Laboratories 6 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer A or BIO?

In the previous week, Bio-Rad Laboratories had 12 more articles in the media than Agilent Technologies. MarketBeat recorded 18 mentions for Bio-Rad Laboratories and 6 mentions for Agilent Technologies. Agilent Technologies' average media sentiment score of 1.00 beat Bio-Rad Laboratories' score of 0.72 indicating that Agilent Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agilent Technologies 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Rad Laboratories 6 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AMN or BIO?

In the previous week, AMN Healthcare Services had 6 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 24 mentions for AMN Healthcare Services and 18 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 0.72 beat AMN Healthcare Services' score of 0.71 indicating that Bio-Rad Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AMN Healthcare Services 8 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Rad Laboratories 6 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BIO.B or BIO?

Bio-Rad Laboratories has a consensus target price of $343.33, indicating a potential downside of 3.53%. Given Bio-Rad Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Bio-Rad Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Rad Laboratories 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bio-Rad Laboratories 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80

Which has better earnings & valuation, BIO.B or BIO?

Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Rad Laboratories $2.58B 3.49 $759.90M $8.25 40.85 Bio-Rad Laboratories $2.58B 3.69 $759.90M $8.25 43.14

Is BIO.B or BIO more profitable?

Company Net Margins Return on Equity Return on Assets Bio-Rad Laboratories 8.59% 3.54% 2.48% Bio-Rad Laboratories 8.59% 3.54% 2.48%

Bio-Rad Laboratories (BIO) Competitors

$355.89 +1.35 (+0.38%)

Closing price 03:59 PM Eastern

Extended Trading

$356.87 +0.98 (+0.27%)

As of 07:34 PM Eastern

Compare

BIO vs. RGEN, TECH, A, AMN, and BIO.B

Should you buy Bio-Rad Laboratories stock or one of its competitors? Bio-Rad Laboratories's main competitors and comparable companies include Repligen (RGEN), Bio-Techne (TECH), Agilent Technologies (A), AMN Healthcare Services (AMN), and Bio-Rad Laboratories (BIO.B). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Bio-Rad Laboratories compare to Repligen?

Repligen (NASDAQ:RGEN) and Bio-Rad Laboratories (NYSE:BIO) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Repligen has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

Bio-Rad Laboratories has a net margin of 8.59% compared to Repligen's net margin of 5.29%. Repligen's return on equity of 5.30% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	5.29%	5.30%	3.79%
Bio-Rad Laboratories	8.59%	3.54%	2.48%

97.6% of Repligen shares are owned by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 0.6% of Repligen shares are owned by company insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Bio-Rad Laboratories has higher revenue and earnings than Repligen. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$738.26M	12.60	$48.89M	$0.73	225.71
Bio-Rad Laboratories	$2.58B	3.69	$759.90M	$8.25	43.14

Repligen presently has a consensus target price of $166.43, indicating a potential upside of 1.01%. Bio-Rad Laboratories has a consensus target price of $343.33, indicating a potential downside of 3.53%. Given Repligen's stronger consensus rating and higher probable upside, analysts plainly believe Repligen is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.94
Bio-Rad Laboratories	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Bio-Rad Laboratories had 11 more articles in the media than Repligen. MarketBeat recorded 18 mentions for Bio-Rad Laboratories and 7 mentions for Repligen. Repligen's average media sentiment score of 1.20 beat Bio-Rad Laboratories' score of 0.72 indicating that Repligen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Rad Laboratories	6 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Repligen beats Bio-Rad Laboratories on 10 of the 17 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Bio-Techne?

Bio-Techne (NASDAQ:TECH) and Bio-Rad Laboratories (NYSE:BIO) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Bio-Techne has a net margin of 9.05% compared to Bio-Rad Laboratories' net margin of 8.59%. Bio-Techne's return on equity of 13.57% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	9.05%	13.57%	10.66%
Bio-Rad Laboratories	8.59%	3.54%	2.48%

Bio-Rad Laboratories has higher revenue and earnings than Bio-Techne. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.26	$73.40M	$0.69	104.57
Bio-Rad Laboratories	$2.58B	3.69	$759.90M	$8.25	43.14

Bio-Techne has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

Bio-Techne currently has a consensus price target of $68.08, indicating a potential downside of 5.65%. Bio-Rad Laboratories has a consensus price target of $343.33, indicating a potential downside of 3.53%. Given Bio-Rad Laboratories' higher possible upside, analysts clearly believe Bio-Rad Laboratories is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	1 Sell rating(s)	13 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.12
Bio-Rad Laboratories	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Bio-Rad Laboratories had 11 more articles in the media than Bio-Techne. MarketBeat recorded 18 mentions for Bio-Rad Laboratories and 7 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.36 beat Bio-Rad Laboratories' score of 0.72 indicating that Bio-Techne is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Rad Laboratories	6 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bio-Techne beats Bio-Rad Laboratories on 10 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Bio-Rad Laboratories (NYSE:BIO) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

Agilent Technologies currently has a consensus price target of $159.35, suggesting a potential upside of 6.73%. Bio-Rad Laboratories has a consensus price target of $343.33, suggesting a potential downside of 3.53%. Given Agilent Technologies' stronger consensus rating and higher possible upside, equities analysts plainly believe Agilent Technologies is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilent Technologies	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.89
Bio-Rad Laboratories	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Agilent Technologies has higher revenue and earnings than Bio-Rad Laboratories. Agilent Technologies is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilent Technologies	$6.95B	6.07	$1.30B	$4.98	29.98
Bio-Rad Laboratories	$2.58B	3.69	$759.90M	$8.25	43.14

In the previous week, Bio-Rad Laboratories had 12 more articles in the media than Agilent Technologies. MarketBeat recorded 18 mentions for Bio-Rad Laboratories and 6 mentions for Agilent Technologies. Agilent Technologies' average media sentiment score of 1.00 beat Bio-Rad Laboratories' score of 0.72 indicating that Agilent Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilent Technologies	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Rad Laboratories	6 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

65.2% of Bio-Rad Laboratories shares are held by institutional investors. 30.3% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Agilent Technologies has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Agilent Technologies has a net margin of 19.55% compared to Bio-Rad Laboratories' net margin of 8.59%. Agilent Technologies' return on equity of 24.33% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilent Technologies	19.55%	24.33%	12.99%
Bio-Rad Laboratories	8.59%	3.54%	2.48%

Summary

Agilent Technologies beats Bio-Rad Laboratories on 12 of the 17 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Bio-Rad Laboratories (NYSE:BIO) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

AMN Healthcare Services has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

AMN Healthcare Services currently has a consensus price target of $30.86, indicating a potential downside of 6.67%. Bio-Rad Laboratories has a consensus price target of $343.33, indicating a potential downside of 3.53%. Given Bio-Rad Laboratories' higher possible upside, analysts plainly believe Bio-Rad Laboratories is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Bio-Rad Laboratories	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Bio-Rad Laboratories has a net margin of 8.59% compared to AMN Healthcare Services' net margin of 3.06%. AMN Healthcare Services' return on equity of 19.92% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	3.06%	19.92%	5.93%
Bio-Rad Laboratories	8.59%	3.54%	2.48%

99.2% of AMN Healthcare Services shares are held by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are held by institutional investors. 1.1% of AMN Healthcare Services shares are held by company insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Bio-Rad Laboratories has lower revenue, but higher earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$2.73B	0.47	-$95.70M	$2.68	12.34
Bio-Rad Laboratories	$2.58B	3.69	$759.90M	$8.25	43.14

In the previous week, AMN Healthcare Services had 6 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 24 mentions for AMN Healthcare Services and 18 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 0.72 beat AMN Healthcare Services' score of 0.71 indicating that Bio-Rad Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AMN Healthcare Services	8 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Rad Laboratories	6 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bio-Rad Laboratories beats AMN Healthcare Services on 9 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Bio-Rad Laboratories?

Bio-Rad Laboratories (NYSE:BIO.B) and Bio-Rad Laboratories (NYSE:BIO) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	3.49	$759.90M	$8.25	40.85
Bio-Rad Laboratories	$2.58B	3.69	$759.90M	$8.25	43.14

Bio-Rad Laboratories has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market.

0.0% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are held by institutional investors. 28.4% of Bio-Rad Laboratories shares are held by insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bio-Rad Laboratories has a consensus target price of $343.33, indicating a potential downside of 3.53%. Given Bio-Rad Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bio-Rad Laboratories	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Bio-Rad Laboratories had 18 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 18 mentions for Bio-Rad Laboratories and 0 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 0.72 beat Bio-Rad Laboratories' score of 0.00 indicating that Bio-Rad Laboratories is being referred to more favorably in the news media.

Company	Overall Sentiment
Bio-Rad Laboratories	Neutral
Bio-Rad Laboratories	Positive

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	8.59%	3.54%	2.48%
Bio-Rad Laboratories	8.59%	3.54%	2.48%

Summary

Bio-Rad Laboratories beats Bio-Rad Laboratories on 10 of the 10 factors compared between the two stocks.

Get Bio-Rad Laboratories News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIO vs. The Competition

Export

Metric	Bio-Rad Laboratories	Life Sciences Tools & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$9.49B	$9.64B	$6.99B	$24.14B
Dividend Yield	N/A	1.47%	2.58%	3.69%
P/E Ratio	43.14	62.43	268.64	29.11
Price / Sales	3.69	108.15	585.15	20.30
Price / Cash	35.38	26.16	28.89	19.38
Price / Book	1.33	5.15	11.31	4.91
Net Income	$759.90M	$56.66B	$3.44B	$1.06B
7 Day Performance	6.92%	4.77%	2.27%	0.17%
1 Month Performance	20.04%	2.15%	-0.23%	2.41%
1 Year Performance	34.56%	26.40%	76.15%	20.41%

Bio-Rad Laboratories Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIO Bio-Rad Laboratories	1.7558 of 5 stars	$355.89 +0.4%	$343.33 -3.5%	+33.8%	$9.49B	$2.58B	43.14	7,450	Earnings Report
RGEN Repligen	3.2127 of 5 stars	$147.06 +4.3%	$166.43 +13.2%	+46.4%	$7.96B	$785.10M	201.45	2,000	Positive News
TECH Bio-Techne	2.7605 of 5 stars	$72.14 +0.1%	$68.08 -5.6%	+43.0%	$11.29B	$1.22B	104.55	3,100	Positive News Upcoming Earnings
A Agilent Technologies	4.6754 of 5 stars	$139.88 +1.1%	$159.35 +13.9%	+29.4%	$39.08B	$6.95B	28.09	18,100
AMN AMN Healthcare Services	2.6907 of 5 stars	$33.00 -1.9%	$29.00 -12.1%	+110.3%	$1.30B	$3.42B	N/A	2,664	Earnings Report Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BIO) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Rad Laboratories (BIO) Competitors

BIO vs. RGEN, TECH, A, AMN, and BIO.B

How does Bio-Rad Laboratories compare to Repligen?

Summary

How does Bio-Rad Laboratories compare to Bio-Techne?

Summary

How does Bio-Rad Laboratories compare to Agilent Technologies?

Summary

How does Bio-Rad Laboratories compare to AMN Healthcare Services?

Summary

How does Bio-Rad Laboratories compare to Bio-Rad Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIO vs. The Competition

Bio-Rad Laboratories Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bio-Rad Laboratories (BIO) Competitors

BIO vs. RGEN, TECH, A, AMN, and BIO.B

How does Bio-Rad Laboratories compare to Repligen?

Which has more volatility & risk, RGEN or BIO?

Is RGEN or BIO more profitable?

Do institutionals and insiders believe in RGEN or BIO?

Which has better valuation and earnings, RGEN or BIO?

Do analysts recommend RGEN or BIO?

Does the media prefer RGEN or BIO?

Summary

How does Bio-Rad Laboratories compare to Bio-Techne?

Do institutionals & insiders believe in TECH or BIO?

Is TECH or BIO more profitable?

Which has higher earnings & valuation, TECH or BIO?

Which has more risk and volatility, TECH or BIO?

Do analysts recommend TECH or BIO?

Does the media prefer TECH or BIO?

Summary

How does Bio-Rad Laboratories compare to Agilent Technologies?

Do analysts rate A or BIO?

Which has preferable earnings and valuation, A or BIO?

Does the media prefer A or BIO?

Do institutionals and insiders have more ownership in A or BIO?

Which has more volatility and risk, A or BIO?

Is A or BIO more profitable?

Summary

How does Bio-Rad Laboratories compare to AMN Healthcare Services?

Which has more volatility and risk, AMN or BIO?

Do analysts prefer AMN or BIO?

Is AMN or BIO more profitable?

Do insiders & institutionals hold more shares of AMN or BIO?

Which has preferable valuation and earnings, AMN or BIO?

Does the media prefer AMN or BIO?

Summary

How does Bio-Rad Laboratories compare to Bio-Rad Laboratories?

Which has better earnings & valuation, BIO.B or BIO?

Which has more risk & volatility, BIO.B or BIO?

Do institutionals and insiders hold more shares of BIO.B or BIO?

Do analysts prefer BIO.B or BIO?

Does the media prefer BIO.B or BIO?

Is BIO.B or BIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIO vs. The Competition

Bio-Rad Laboratories Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools